JoinCare has announced a new strategic seed round with participation from Titans Ventures, DI Foundation, and Candaq Ventures. The company said the proceeds will be used to upgrade its core infrastructure and the CareAgents AI-assisted research system, while also expanding its global pipeline of early-stage biopharmaceutical projects and its network of scientific and medical advisors. The funding will also support development of JoinCare’s ecosystem applications and Launchpad.
JoinCare is building an open DeSci incubation network focused on early-stage biopharmaceutical innovation. By linking research teams, scientific and medical experts, ecosystem builders, and community participants, the platform aims to support projects across discovery, scientific evaluation, and collaborative incubation. Looking ahead, JoinCare plans to extend this framework to research institutions and innovation teams worldwide and develop an AI-powered distributed biopharmaceutical innovation network.
JoinCare has completed a new strategic seed round, with Titans Ventures, DI Foundation, and Candaq Ventures participating in the financing.
The company said the new capital will be used to upgrade its core infrastructure and the CareAgents AI-assisted research system. It also plans to use the funds to expand its global pipeline of early-stage biopharmaceutical projects and its network of scientific and medical advisors, while pushing ahead with ecosystem applications and Launchpad development.
An open DeSci incubation network for early-stage biopharma
JoinCare is building an open decentralized science, or DeSci, incubation network focused on early-stage biopharmaceutical innovation. The platform connects research teams, scientific and medical experts, ecosystem builders, and community participants, and is designed to support projects from discovery and scientific evaluation through collaborative incubation.
Global expansion plan
JoinCare said it plans to expand the system to research institutions and innovation teams worldwide. Its stated goal is to build an AI-powered distributed biopharmaceutical innovation network.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
